Products perampanel
perampanel Phase 2 Completed ⚡ Active Refractory Partial Seizures
Refractory Partial Seizures
Jun 17, 2009 → Oct 31, 2016
About perampanel perampanel is a phase 2 stage product being developed by Eisai for Refractory Partial Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT00903786. Target conditions include Refractory Partial Seizures.
Clinical Trials (20) NCT ID Phase Status Start Completion Indication NCT01871233 Pre-clinical Completed — — Partial Onset Seizures NCT02307578 Pre-clinical Completed — — Primary Generalized Tonic-Clonic or Partial Onset Seizures NCT05533814 Approved Completed Oct 19, 2022 Jan 23, 2025 Epilepsy NCT04252846 Pre-clinical Completed Jul 20, 2020 Jan 12, 2023 Idiopathic Generalized Epilepsy NCT03836924 Pre-clinical Completed Feb 18, 2019 Mar 1, 2020 Partial Onset Seizures NCT03424564 Phase 1 Completed Mar 20, 2018 May 25, 2018 Healthy Subjects NCT03288129 Approved Completed Aug 23, 2017 Apr 27, 2021 Partial Onset Seizures NCT02914314 Phase 2 Completed Feb 20, 2017 Apr 25, 2023 Epilepsy NCT02849626 Phase 3 Completed Nov 16, 2016 Dec 6, 2021 Partial-Onset or Primary Generalized Tonic-Clonic Seizures NCT02726074 Approved Completed May 3, 2016 Apr 26, 2018 Epilepsy NCT04230044 Pre-clinical Completed Apr 11, 2016 Jul 3, 2017 Epilepsy NCT04257604 Pre-clinical Completed Jan 3, 2016 Apr 30, 2019 Partial Seizures NCT02727101 Approved Terminated Nov 1, 2015 Jul 1, 2017 Epilepsy NCT02427607 Phase 3 Completed May 12, 2015 Nov 9, 2016 Epilepsy NCT02279485 Phase 1 Completed Sep 1, 2014 Jan 1, 2015 Healthy Subjects NCT02033902 Pre-clinical Completed Jun 6, 2014 Jan 31, 2018 Epilepsy NCT01527006 Phase 2 Completed Jan 1, 2012 Apr 1, 2015 Central Nervous System NCT00903786 Phase 2 Completed Jun 17, 2009 Oct 31, 2016 Refractory Partial Seizures NCT00735397 Phase 3 Completed Oct 1, 2008 Sep 1, 2014 Epilepsy NCT00505622 Phase 3 Terminated Jul 1, 2007 Apr 1, 2008 Parkinson's Disease
Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 Valemetostat Tosylate Daiichi Sankyo Phase 2 Enzalutamide Astellas Pharma Phase 2 ASP1650 Astellas Pharma Phase 2 YM598 Astellas Pharma Phase 2 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib + Everolimus Eisai Phase 1/2 perampanel + perampanel + perampanel + Placebo Eisai Phase 3 Eribulin mesilate + Irinotecan hydrochloride Eisai Phase 1/2 rabeprazole sodium Eisai Pre-clinical Lenvatinib Eisai Phase 2 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 Tazemetostat Eisai Phase 2 Rufinamide Eisai Phase 3 Lenvatinib + Moxifloxacin 400 mg + Placebos (matched to 4 mg and 10 mg lenvatinib capsules). Eisai Phase 1
Other Products from Eisai